Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Dare Bioscience, Inc. Common Stock

DARE

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Last trade $0.4384
Day change -$0.1458 (-24.96%)
Day range $0.416 – $0.644
Volume 804,437
Market cap $11M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$11.41M
Price / earnings
—
Price / book
-20.37×
Price / sales
8.35×
EV / sales
-0.77×
EV / EBITDA
0.12×

Profitability

Earnings per share
-$0.56
Return on assets
-49.12%
Return on equity
1,961.64%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.29×
Current ratio
0.99×
Quick ratio
0.99×
Cash ratio
0.75×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.76M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DARE, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$187.55K$152.46K$1.02M$2.26K-$21.17K$25.43K—$41.69K
Cost of revenue$319.89K$242.33K$295.8K$0$0$0$0$0
Gross profit-$132.34K-$89.87K$727.88K$2.26K-$21.17K$25.43K—$41.69K
Selling, general and administrative$2.59M$2.25M$1.58M$2.5M$2.38M$2.31M—$2.04M
Research and development$241.97K$660.46K$622.04K$1.18M$1.43M$2.3M—$2.68M
Total operating expenses$2.84M$2.91M$2.2M$3.67M$3.81M$4.61M—$4.72M
Operating income-$2.97M-$3M-$1.47M-$3.67M-$3.83M-$4.58M—-$4.68M
Interest expense$0$0$0$0$0$0—$0
Income before taxes-$2.98M-$3M-$1.44M-$3.56M-$4.02M-$4.38M—-$4.7M
Income taxes$0$0$0$0$0$0—$0
Net income-$2.98M-$3M-$1.44M-$3.56M-$4.02M-$4.38M—-$4.7M
Net income attributable to common shareholders-$2.98M-$3M-$1.44M-$3.56M-$4.02M-$4.38M—-$4.7M
EBITDA-$2.4M-$2.44M-$936.87K-$3.19M-$3.37M-$4.41M$6.37K-$4.67M
Basic earnings per share-$0.20-$0.21-$0.10-$0.28-$0.45-$0.50—-$0.55
Diluted earnings per share-$0.20-$0.21-$0.10-$0.28-$0.45-$0.50—-$0.55

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Dare Bioscience reported a Q3 loss of $0.18 per share, missing the consensus estimate of $0.13 loss by 38.46%. The company posted revenues of $0.05 million, missing estimates by 99.19%. DARE shares have declined 65.9% year-to-date versus the S&P 500's 10.5% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

The Motley Fool

Daré Bioscience Posts Narrower Q2 Loss

Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.

GlobeNewswire Inc.

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Daré Bioscience announced positive findings from a Phase 2b study of its investigational topical cream Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD). The study showed consistent results from patient-reported outcome measures, regardless of recall period, supporting the use of longer recall intervals which are less burdensome for patients.

Investing.com

Dare Bioscience regains Nasdaq compliance with bid price - Investing.com

Dare Bioscience, a biopharmaceutical company focused on women's health, has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock achieved the necessary closing bid price of $1.00 or more per share over 10 consecutive trading sessions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 1, 20241-for-12reverse split